Q-omics provides the consensus-scored RPL41 profile across patient tissues and cancer cell-line models. RPL41 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL41 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RPL41 RNA expression shows 17,166 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RPL41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL41 survival associations across molecular data types. RPL41 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL41 RNA expression–survival associations across cancer types. High RPL41 expression shows unfavorable associations in ACC, KIRP and LIHC, but favorable associations in MESO, UVM and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL41 RNA expression.
This table summarizes RPL41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL41 shows higher tumor expression in KIRC, LIHC, KIRP, CHOL, COAD and LUSC. The KIRC box plot shows higher RPL41 RNA expression in tumor versus normal tissue (log2 FC = +0.898, t-test p < 0.001).
This table shows molecular features associated with RPL41 in patient tissues and cancer cell lines. In patient samples, RPL41 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
